New RAD202 data confirms positive tumor uptake

New RAD202 data confirms positive tumor uptake

Radiopharm Theranostics (RAD:AU) has announced New RAD202 data confirms positive tumor uptake

Download the PDF here.

The Conversation (0)
Appendix 4E and Preliminary Final Report

Appendix 4E and Preliminary Final Report

Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
RAD receives IND approval from US FDA for Betabart (RV-01)

RAD receives IND approval from US FDA for Betabart (RV-01)

Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 5 Canadian Biotech Stocks in 2026

Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.Here, the Investing News Network profiles the five best-performing Canadian biotech stocks... Keep Reading...
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 Small-cap Biotech Stocks in 2026

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has climbed back to multi-year highs in 2026, underscoring renewed strength in the biotech sector despite broader market volatility. As of November 4, the index stood at 7,463.68, up over 30 percent year-to-date. The rise shows that investors are... Keep Reading...
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026

Bria-OTS+â„¢ demonstrates broad immune activation and sustained cancer-cell killing across multiple tumor modelsBriaPro data highlights BP-80 tolerability in primates and advances in tumor-targeted checkpoint inhibition briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or... Keep Reading...
Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH

(TheNewswire) Third pharmaceutical company relationship entered Kelowna, British Columbia November 4, 2026 TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered into an Agreement with an... Keep Reading...
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 

Four presentations highlight BriaCell's Bria-OTS+â„¢ cellular immunotherapy platform and BriaPro's CD80-based immunotherapy programsIn vitro Bria-OTS+ studies demonstrate immune-cell activation and tumor-cell killing across breast, prostate and lung cancer modelsBriaPro data describes BP-80... Keep Reading...
Lexaria Celebrates its 70th Patent Award

Lexaria Celebrates its 70th Patent Award

KELOWNA, BC / ACCESS Newswire / October 28, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company as a result of its ongoing... Keep Reading...

Interactive Chart

Latest Press Releases

Related News